Farcast Biosciences: Maneesh Arora

Sep 05, 2019

Maneesh Arora has joined Boston-based diagnostics firm Farcast Biosciences as president and CEO. Arora previously served as COO and a member of the board of directors of Exact Sciences. He also previously was CFO of Third Wave Technologies, which was acquired in 2008 by Hologic for $582 million. Farcast, formerly called Mitra Biotech, has developed an ex vivo platform for evaluating tumor response to drug treatments.

Breaking News

Plasmid Transfer Let Cholera Pathogen in Yemen Become Multidrug Resistant, Study Suggests
Harbinger Health Raises $140 Million in Series B Financing
BioMérieux's BioFire Defense Secures $18.8M US DoD Contract for Infectious Disease Testing
Biora Therapeutics Settles Claims of Misleading Genetic Testing Advertisements
Genetic Overlap Between Schizophrenia, Cardiovascular Disease Risk Uncovered by GWAS Analysis

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.